Abeona Therapeutics Inc. (ABEO) Stock
Fundamentals
Recent news

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
ABEO

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
ABEO

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
ABEO

ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
ABEO
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.12 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 9 articles
published over the past 14 days
Latest news

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
ABEO

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
ABEO

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
ABEO

ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
ABEO

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
ABEO

Abeona Therapeutics Q2 Earnings Call Highlights
Abeona Therapeutics Q2 Earnings Call Highlights
ABEO

Abeona Therapeutics Q1 Earnings Call Highlights
Abeona Therapeutics Q1 Earnings Call Highlights
ABEO

The 7 Most Undervalued Penny Stocks to Buy in October 2023
The 7 Most Undervalued Penny Stocks to Buy in October 2023
ABEO

3 Biotech Blockbusters to Turn $5,000 Into $50,000
3 Biotech Blockbusters to Turn $5,000 Into $50,000
ABEO
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, CEO & Director | 1976 |
| Mr. Joseph Walter Vazzano CPA | Chief Financial Officer | 1984 |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Chief Legal Officer | 1969 |
| Mr. Brian Kevany Ph.D. | Chief Technical & Scientific Officer | — |
| Mr. Gregory Gin | Vice President of Investor Relations & Corporate Communications | — |
| Ms. Gianine Esposito | Senior VP & Chief People Officer | — |
| Mr. Jon Voss | VP & Head of Quality | 1960 |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | SVP, Chief Commercial Officer & Head of Business Development | 1979 |
| Mr. Carl Denny | Senior Vice President of Regulatory Affairs | — |
| Ms. Megan Callan | Vice President & Head of Quality | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.8 | -26.1 | -23.1 | -43.8 | ||||||||
| 2022 | -31.0 | -7.9 | +12.4 | -36.1 | -21.9 | +34.0 | -17.3 | -6.7 | -12.6 | +39.9 | -23.3 | -20.6 |
| 2023 | -11.9 | -13.6 | +23.7 | +8.5 | -4.6 | +31.7 | -20.6 | +33.8 | +0.5 | -5.7 | +25.3 | +7.5 |
| 2024 | -26.4 | +60.5 | -7.2 | -46.4 | +12.0 | -6.2 | +16.7 | +18.5 | +15.8 | -0.8 | +2.2 | -12.1 |
| 2025 | -6.3 | -4.7 | -6.5 | +47.4 | -9.2 | -9.6 | +14.4 | +5.2 | -22.9 | -8.9 | +6.1 | +10.3 |
| 2026 | -4.1 | -1.0 | -11.5 | +19.2 | +6.4 | +9.8 | +6.1 | -8.5 | -9.7 |



